Halozyme Therapeutics Inc.

Halozyme Therapeutics is a biopharma technology platform company that provides solutions to improve patient experience and outcomes. The company's approved product and its collaborators' approved products and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. The company refers to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as its ENHANZE? Drug Delivery Technology (ENHANZE). The company licenses the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.
  • TickerHALO
  • ISINUS40637H1095
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Sid Rajeev
  • Sid Rajeev
HALO Halozyme Therap... (Health Care)

Halo Collective Inc. (NEO: HALO / OTCQX: HCANF / GERMANY: A9KN) Expect...

Halo Collective Inc. (NEO: HALO / OTCQX: HCANF / GERMANY: A9KN) Expecting a 3x Increase in Revenue This Year. Visit our website: /. HALO is an FRC Top Pick.

Sid Rajeev
  • Sid Rajeev
HALO Halozyme Therap... (Health Care)

Halo Collective Inc.(NEO: HALO / OTCQX: HCANF / GERMANY: A9KN)- Expect...

Fundamental Research Corp has issued a report entitled “Halo Collective Inc.(NEO: HALO / OTCQX: HCANF / GERMANY: A9KN)- Expecting Revenue to More Than Triple in 2021 – Initiating Coverage” and dated March 11, 2021. Halo is an FRC Top Pick. The full report is now at

HALO Halozyme Therap... (Health Care)

HALOZYME THERAPEUTICS sees an upgrade to Positive due to a better fund...

The general evaluation of HALOZYME THERAPEUTICS (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date February 16, 2021, the closing price was USD 49.09 and its potential was estimated at USD 57.36.

HALO Halozyme Therap... (Health Care)

Halozyme Therapeutics Inc: 1 director sold

A director at Halozyme Therapeutics Inc sold 12,000 shares at 42.577USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

 PRESS RELEASE
HALO Halozyme Therap... (Health Care)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Co...

NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces it has commenced an investigation of Halozyme Therapeutics, Inc. (NASDAQGS: HALO) concerning possible breaches of fiduciary duty. To obtain additional information, go to: http://www.zlkdocs.com/HALO-Info-Request-Form-6557 or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. Levi & Korsinsky is a national firm with offices in New Yor...

HALO Halozyme Therap... (Health Care)

Halozyme Therapeutics Inc: 1 director sold

A director at Halozyme Therapeutics Inc sold 12,000 shares at 42.577USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

 PRESS RELEASE
HALO Halozyme Therap... (Health Care)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Co...

NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces it has commenced an investigation of Halozyme Therapeutics, Inc. (NASDAQGS: HALO) concerning possible breaches of fiduciary duty. To obtain additional information, go to: http://www.zlkdocs.com/HALO-Info-Request-Form-6557 or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. Levi & Korsinsky is a national firm with offices in New Yor...

Sid Rajeev
  • Sid Rajeev
HALO Halozyme Therap... (Health Care)

Halo Collective Inc. (NEO: HALO / OTCQX: HCANF / GERMANY: A9KN) Expect...

Halo Collective Inc. (NEO: HALO / OTCQX: HCANF / GERMANY: A9KN) Expecting a 3x Increase in Revenue This Year. Visit our website: /. HALO is an FRC Top Pick.

Sid Rajeev
  • Sid Rajeev
HALO Halozyme Therap... (Health Care)

Halo Collective Inc.(NEO: HALO / OTCQX: HCANF / GERMANY: A9KN)- Expect...

Fundamental Research Corp has issued a report entitled “Halo Collective Inc.(NEO: HALO / OTCQX: HCANF / GERMANY: A9KN)- Expecting Revenue to More Than Triple in 2021 – Initiating Coverage” and dated March 11, 2021. Halo is an FRC Top Pick. The full report is now at

HALO Halozyme Therap... (Health Care)

Update: Termination of coverage

Edison Investment Research is terminating coverage on Halozyme Therapeutics (HALO). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

HALO Halozyme Therap... (Health Care)

Update: Hope in pancreatic cancer

Halozyme hosted an analyst day in January, which focused on its PEGPH20 programme in pancreatic and non-small cell lung cancer (NSCLC). It presented interim data from Stage 1 of a Phase II trial where PEGPH20 in combination with the standard of care demonstrated a 71% response rate, compared to just 29% for the standard of care alone. Also, progression-free survival more than doubled in the treatment arm. We have increased our valuation to $15.31 per share from $11.70 per share.

HALO Halozyme Therap... (Health Care)

HALOZYME THERAPEUTICS sees an upgrade to Positive due to a better fund...

The general evaluation of HALOZYME THERAPEUTICS (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date February 16, 2021, the closing price was USD 49.09 and its potential was estimated at USD 57.36.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch